drugset / Trial / NCT01666080

Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

NCT01666080

NaSingle-groupOpen-labelTreatment

Summary

This is a treatment guideline for a second or greater allogeneic hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) in patients with non-malignant or malignant diseases. This regimen, consisting of busulfan, fludarabine, and low dose total body irradiation (TBI), is designed to promote engraftment in patients who failed to achieve an acceptable level of donor-derived engraftment following a previous allogeneic HCT.

Timeline

Start
2012-08
Primary completion
2027-06
Completion
2028-06

Drugs

EvaluationDrugModalityDoseRoute
Background Busulfan Small molecule 0.4 mg/kg Intravenous
Background Busulfan Small molecule 0.5 mg/kg Intravenous
Background Fludarabine Small molecule 40 mg/m2 Intravenous
Background Levetiracetam Other / unclassified